Your browser doesn't support javascript.
loading
MOR202, a novel anti-CD38 monoclonal antibody, in patients with relapsed or refractory multiple myeloma: a first-in-human, multicentre, phase 1-2a trial.
Raab, Marc S; Engelhardt, Monika; Blank, Antje; Goldschmidt, Hartmut; Agis, Hermine; Blau, Igor W; Einsele, Hermann; Ferstl, Barbara; Schub, Natalie; Röllig, Christoph; Weisel, Katja; Winderlich, Mark; Griese, Janine; Härtle, Stefan; Weirather, Johannes; Jarutat, Tiantom; Peschel, Christian; Chatterjee, Manik.
Afiliación
  • Raab MS; Department of Medicine V, University Hospital Heidelberg, Heidelberg, Germany. Electronic address: marc.raab@med.uni-heidelberg.de.
  • Engelhardt M; Hematology and Oncology Department, Medical University Hospital, Freiburg, Germany.
  • Blank A; Department of Clinical Pharmacology and Pharmacoepidemiology, University Hospital Heidelberg, Heidelberg, Germany.
  • Goldschmidt H; Department of Medicine V, University Hospital Heidelberg, Heidelberg, Germany; National Center for Tumor Diseases, Heidelberg, Germany.
  • Agis H; Department of Medicine I, University Hospital of Internal Medicine -Allgemeines Krankenhaus Wien, Vienna, Austria.
  • Blau IW; Department of Internal Medicine III, Charité Campus Benjamin Franklin, Berlin, Germany.
  • Einsele H; Department of Internal Medicine II, University Hospital of Würzburg, Würzburg, Germany.
  • Ferstl B; Department of Internal Medicine 5, Hematology and Oncology, Friedrich-Alexander-University Erlangen-Nuremberg, Erlangen, Germany.
  • Schub N; Department of Medicine, University Hospital Schleswig-Holstein, Division of Stem Cell Transplantation and Immunotherapy, Kiel, Germany.
  • Röllig C; Department of Medicine I, University Hospital Carl Gustav Carus, Dresden, Germany.
  • Weisel K; Department of Oncology, Hematology and Bone Marrow Transplantation with Section of Pneumology, University Medical Center Hamburg-Eppendorf, Hamburg; Universitätsklinikum Tübingen, Tübingen, Germany.
  • Winderlich M; MorphoSys AG, Planegg, Germany.
  • Griese J; MorphoSys AG, Planegg, Germany.
  • Härtle S; MorphoSys AG, Planegg, Germany.
  • Weirather J; MorphoSys AG, Planegg, Germany.
  • Jarutat T; MorphoSys AG, Planegg, Germany.
  • Peschel C; Department of Internal Medicine III, Technical University of Munich, Munich, Germany.
  • Chatterjee M; Translational Oncology, Comprehensive Cancer Center Mainfranken, University Hospital of Würzburg, Würzburg, Germany.
Lancet Haematol ; 7(5): e381-e394, 2020 May.
Article en En | MEDLINE | ID: mdl-32171061
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Anticuerpos Monoclonales Humanizados / Antineoplásicos Inmunológicos / Mieloma Múltiple Tipo de estudio: Clinical_trials Límite: Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Lancet Haematol Año: 2020 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Anticuerpos Monoclonales Humanizados / Antineoplásicos Inmunológicos / Mieloma Múltiple Tipo de estudio: Clinical_trials Límite: Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Lancet Haematol Año: 2020 Tipo del documento: Article